Does Revumenib Interact with Mao Inhibitors?
CDI records a moderate classification for Revumenib and Mao Inhibitors. The stored summary is: Concomitant use increases revumenib systemic exposure, which may increase the risk of adverse reactions. Dose reduction of REVUFORJ is required. The mechanism involves strong cyp3a4 inhibitors reduce metabolism of revumenib, which is primarily metabolized by cyp3a4. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Moderate
- Management
- Monitor for effects
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
Strong CYP3A4 inhibitors reduce metabolism of revumenib, which is primarily metabolized by CYP3A4
What To Tell Your Doctor or Pharmacist
If you are taking Revumenib and your doctor is considering prescribing Mao Inhibitors (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider